Unlike treatment with VCR in vivo, the highest dose of RCM1-NPFA reduced tumor-associated angiogenesis which was quantified as CD31+-vessel coverage within RMS tumors in mice (Supplementary Figure S3E). Here, TNNI3 is linked to neoplasm.